Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The press release announces the appointment of Yasunari Harada as Chief Financial Officer and a director of TOYO Co., Ltd, effective July 1, 2026. While the disclosure also mentions the concurrent resignation of the prior CFO, Taewoo "Raymond" Chung, the principal disclosed action is Harada's appointment to a senior executive and board position. The appointment of a CFO with 30+ years of senior leadership experience at major investment banks is material to a reasonable investor's assessment of the company's financial strategy and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Allen C. Harper as Interim Chief Executive Officer and Principal Executive Officer of Rocky Mountain Chocolate Factory, Inc., effective June 29, 2026. While the disclosure also mentions Harper's resignation from his prior CEO role at American Heritage Railways and includes compensatory arrangements ($200,000 in cash and restricted stock units), the principal disclosed action is the appointment to the CEO position. This is a material executive appointment affecting the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
The Item 5.02 disclosure centers on two distinct executive actions: (1) Peter O'Rourke's appointment as President of Quantum Drones (a wholly owned subsidiary) under a new employment agreement with specified compensation (base salary of $20,833.33/month, stock options for 112,859 shares at $1.45/share), and (2) Louis Buffalino's appointment as a director and committee member effective July 1, 2026. While the section also includes compensatory details, the principal disclosed actions are the appointments themselves. The appointment of a President to a material subsidiary and a director to the Board are material governance events affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 5.02
Following the merger closing, Envirotech Vehicles appointed a new executive leadership team effective immediately: Chris Young as CEO and Class II director, Simon Yu as President, Jason Maddox as CFO, and three additional C-suite officers (David Shiue, Gary Chen, and Jenny Yang). Phillip W. Oldridge resigned as Chairman and CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
Paul Carreiro was appointed as President and Chief Executive Officer effective July 6, 2026. The appointment includes compensatory arrangements consisting of LTIP Units and a Retention Agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
The filing discloses the appointment of Mark Kelly as Chief Financial Officer effective August 3, 2026, along with the concurrent retirement of interim CFO Gayle Jardine. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background, compensation terms (£165,000 base salary, $40,000 restricted stock grant), and probationary conditions. This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-06
The 6-K discloses the appointment of Mr. Xu Jiang as a director of DarkIris Inc., effective July 3, 2026, approved by the Board and nominating committee. While the filing also mentions Ms. Hong Yuanfang's resignation, the principal disclosed action is the appointment of a new director (who is also the existing CFO). This is material as it represents a change in board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
The filing discloses the appointment of Joaquin Martin, the Company's Chief Executive Officer of the Americas & Global Vice-Chairman, to the Board of Directors effective July 3, 2026, following recommendation by the Nominating and Corporate Governance Committee. While the filing also mentions the concurrent resignation of Manuel Vizcaino as co-chairman and board member, the principal disclosed action centers on the appointment of an existing senior executive to the board, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 1.01
Item 1.01 discloses the appointment of John Spencer, the Company's Senior Controller, to serve as Chief Financial Officer effective July 1, 2026, along with an Executive Employment Agreement. While Item 5.02(e) also mentions compensatory arrangements (an option award of $25,000), the principal disclosed action in Item 1.01 is the appointment to the CFO role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
The filing discloses the appointment of Scott Gallagher as Interim Chief Financial Officer and W. Scott McBride as Interim Treasurer and Secretary, effective July 1, 2026, following the resignation of Braden Glasbergen as CFO, Treasurer and Secretary on June 30, 2026. While both a departure and appointments occur, the principal disclosed action centers on the appointments of two interim officers to fill critical financial and administrative roles. The appointments are material as they affect the registrant's executive leadership structure and financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and sole member of the Board of Directors on June 29, 2026, replacing Aitan Zacharin who resigned from all officer positions. Sanchez Talavera brings substantial transaction experience with over $2.5 billion in aggregate transaction value.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the election of Carl R. Christenson as a Class A director of Moog Inc., effective July 1, 2026, following an increase in board size from nine to ten directors. This is a clear appointment of a director with significant public company and executive leadership experience (former CEO and Chairman of Altra Industrial Motion Corp., current IDEX board member). Director appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-06
Item 5.02
Kathryn M. JohnBull was appointed President and CEO effective July 1, 2026, and Steven V. Oroho, Jr. was appointed Chief Financial Officer and Treasurer effective July 1, 2026. The filing also discloses the retirement of Zachary C. Parker as CEO, with detailed employment agreements and compensation arrangements for the new executives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 8.01
The filing discloses the appointment of two named executives: Scott David Miller as Product & Analytics Lead (effective July 2, 2026) and Thomas Bennett as Data Science / Modeling Lead (effective July 3, 2026). Both appointments are presented as part of management's strategic expansion of technical capabilities and are material to the company's operational and product development strategy. While the Item 8.01 caption is "Other Events," the substance is clearly executive appointment(s) that strengthen core technical infrastructure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Lynn Seely, M.D. as a new Class III director to AbCellera's Board of Directors effective June 30, 2026. The principal disclosed action is a person taking a governance role. Dr. Seely is an independent director with substantial biopharmaceutical executive experience, including CEO roles at Lyell Immunopharma and Myovant Sciences, and prior board service at Blueprint Medicines (acquired for $9.1 billion). This is a material governance event affecting the composition and expertise of the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Aleksandr Zhandov as Chief Operating Officer and Deputy Chief Executive Officer effective July 6, 2026. While the disclosure includes employment agreement terms (base salary of $120,000, at-will employment, discretionary bonuses and equity), the principal disclosed action is the appointment of a named executive to a senior officer role reporting to the CEO. This is a material governance event affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
Melissa G. Podruzny was appointed as Interim CFO effective July 1, 2026, following the departure of CFO Joy L. Mbanugo on June 29, 2026. Ms. Podruzny's compensation includes a CAD $141,180 base salary, CAD $30,000 interim premium, CAD $20,000 transition bonus, and a 50,000-share stock option grant with a 24-month vesting schedule.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
The filing discloses the appointment of two individuals, David Gaertner and David Mutina, to the Company's Board of Directors on July 2, 2026. Item 5.02 explicitly covers director appointments, and the prose confirms both individuals were appointed to serve as board members with their qualifications and backgrounds detailed. This is a material governance event affecting the composition of the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
Shawn P. Payne was elected as a Director and appointed to serve as a member of the Project Risk Committee and chair of the Strategy Committee, effective July 1, 2026, in connection with his previously announced appointment as President and Chief Executive Officer. The principal disclosed action is a person taking on significant leadership roles, making this an executive appointment. This is material as it involves a CEO appointment and board election.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Nicholas Parker as Executive Vice President, Worldwide Field Operations, effective August 24, 2026, along with detailed compensation terms including a $1M base salary, $5M sign-on bonus, and $40M in equity grants. While the section also mentions Ajay K. Puri's retirement, the principal disclosed action centers on Parker's appointment to a senior executive role with material compensation arrangements. This is a significant leadership transition at a major technology company and would affect investor assessment of operational continuity and capital allocation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
The filing announces the appointment of Mr. Botao Shi as interim chief financial officer of Concord Medical, effective June 30, 2026. While the filing also discloses the resignation of the prior CFO, Mr. Wei Jiang, the principal disclosed action is the appointment of a new CFO to fill that role. The appointment of a CFO is a material executive change affecting the registrant's financial leadership and would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses both a director departure (David Sambur's resignation effective July 2, 2026) and a director appointment (Christine Duffy's appointment to fill the vacancy). While both events occur, the principal disclosed action centers on the appointment of Ms. Duffy to the board, with her qualifications, compensation terms, and indemnification agreement detailed. The departure is presented as a mechanical consequence of Apollo Investors' reduced designation rights following their public offering. The appointment of a qualified director with significant hospitality industry experience is the substantive event requiring investor attention.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
EX-99.1
The exhibit announces the appointment of Ms. Xiaojing Lu as a director and member of two board committees, effective July 1, 2026. Although the announcement also discloses the concurrent resignation of Ms. Yifang Xu, the principal disclosed action is the appointment of a new director with significant internal operational experience and board committee responsibilities. This is a material governance event affecting board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-02
EX-99.1
The exhibit announces the appointment of Mr. Ying Tian as Chief Financial Officer of iQIYI, effective immediately. This is a material executive appointment to a named officer position (CFO), which would affect a reasonable investor's assessment of the company's financial leadership and governance. The concurrent step-down of Ms. Ying Zeng from Interim CFO is secondary to the principal appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
The disclosure centers on the election of Tali Farhadian Weinstein to the Board of Directors of Consolidated Edison, Inc. and Consolidated Edison Company of New York, Inc., effective July 1, 2026. She was also appointed to two board committees. This is a clear board appointment, which is a material governance event affecting the composition of the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
Francis A. Braun III and Dylan G. Petre were appointed to the Board of Directors effective July 1, 2026 upon listing, with Braun designated as Audit Committee chair and Petre appointed to the Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Michael Blitzer was appointed as director and Chairman of the Board, and Kevin Shannon was appointed as Chief Executive Officer, both effective June 26, 2026, in connection with the Business Combination Agreement with Inflection Point Asset Management LLC.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 83%
filed 2026-07-02
Item 5.02
Dr. Craig Eagle was appointed to OS Therapies' Board of Directors effective June 1, 2026, transitioning from Chief Medical Advisor. Dr. Eagle brings substantial oncology and pharmaceutical leadership experience, including prior roles as CMO at Guardant Health, VP Medical Affairs at Genentech, and senior positions at Pfizer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
The Board appointed Joanna Lohkamp as an interim director, Audit Committee member, and Remuneration Committee chair, effective July 1, 2026. This is a clear executive/board appointment that would materially affect investor assessment of the company's governance and leadership structure, particularly given her committee roles overseeing audit and compensation matters.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-02
The filing discloses both the resignation of Mark Pickering as CFO and Executive Officer (effective June 29, 2026) and the appointment of Carrie Rosorea as CFO and Executive Officer on the same date. While both events occur, the principal disclosed action is the appointment of a new CFO to fill the vacancy, making exec_appointment the primary classification. CFO changes are material to investors assessing management continuity and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Dr. David S. Shields was appointed as a Class I director and Compensation Committee member of CapsoVision, Inc., effective July 1, 2026, bringing deep clinical expertise in capsule endoscopy to the Board. The appointment also coincided with Dr. Joanne Imperial's resignation from the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-02
Item 8.01
The disclosure centers on the Board's appointment of Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer with expanded functional oversight of commercial functions, medical affairs, regulatory and clinical. While Michael Seckler's departure is mentioned, the principal action disclosed is Hurlburt's appointment to an expanded executive position. The expansion of her role and new title constitute a material change in executive leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Matthew S. Diffley was appointed as Principal Accounting Officer (PAO) of Live Oak Bancshares, Inc., effective July 1, 2026, replacing interim PAO Walter J. Phifer. While the disclosure also mentions an expected RSU grant of $200,000, the principal disclosed action is the appointment of a named executive to a key officer role. The appointment of a PAO is material to investors as it affects the registrant's financial reporting and internal controls oversight.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
The 6-K discloses the appointment of Mr. Tee Kok Siong as Chief Financial Officer of Ryde Group Ltd, effective July 3, 2026, to fill the vacancy created by Mr. Lang Chen Fei's resignation. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite officer role, which is material to investors assessing the company's financial leadership and governance. The detailed biographical information and professional qualifications provided underscore the materiality of this executive transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
The filing discloses the appointment of two directors, Danina Fisher and Gary S. Stetz, II, to the Board of Directors of Hepion Pharmaceuticals, effective immediately on July 1, 2026. This is a clear executive appointment under Item 5.02, with the principal disclosed action being persons taking board roles. The disclosure notes a family relationship between Mr. Stetz and Gary Stetz (the interim CEO signing the filing), which adds governance significance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
UPAY, Inc. appointed Wynand Johannes Jordaan as a non-executive director effective July 1, 2026. The appointment includes a compensatory arrangement of 200,000 restricted shares vesting over 24 months and is intended to strengthen the board's technology, software architecture, systems design, and digital infrastructure expertise.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-02
Item 5.02
Lucid announced multiple senior executive appointments to its Global Leadership Team, including Alexander De Bock as Chief Financial Officer (with $750,000 base salary, $1.1M signing bonus, $7.5M equity grants, and up to $2.5M performance-based bonuses), Raja Ramana Macha as Chief Technology Officer, Billy Hayes as Chief Customer Officer, Hugo Martinho as Chief Transformation Officer, Kay Stepper as Chief Digital Officer, and a promotion of Christian Appel, alongside the departure of incumbent CFO Taoufiq Boussaid. These appointments are intended to simplify the organization, sharpen accountability, and improve execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses multiple executive appointments effective July 1, 2026: Robert Wright appointed Chief Financial Officer (replacing Mark Hobbs), Misty Lavender appointed Executive Vice President, General Counsel and Corporate Secretary (replacing Denise McWatters), and Mohit Bhardwaj appointed to a new Executive Vice President, New Energy role. While the section also includes compensation amendments and a departure (McWatters transitioning to consulting), the principal disclosed actions center on the appointments of new officers to key leadership positions, making exec_appointment the most salient classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-02
EX-99.1
The press release announces the appointment of Marvin Singer to the board of directors as the representative for Ataraxia Capital, pursuant to an Investor's Rights Agreement. This is a clear executive/governance appointment of a director with relevant experience in corporate law, M&A, and corporate governance. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
Simon Kearney was elected to Nixxy's Board of Directors on June 29, 2026. The disclosure centers on his appointment as a director and includes his background, compensation structure (50,000 initial shares, annual equity grants, and $2,500 monthly payment), and confirmations of no conflicts or family relationships. This is a clear director appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointments of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the fund manager) on an interim basis, effective July 2, 2026, with Masci also appointed to the Board of Managers and as Principal Financial and Accounting Officer of the registrant. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointments of two executives to critical financial leadership roles. This is material as it affects the fund's financial oversight and reporting structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as CFO appointments directly affect investor confidence in financial reporting and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-02
Item 5.02
The filing discloses two director-level events: the resignation of Dr. Ming-Fu Chiang on June 27, 2026, and the election of Nasim Shomali as a Class II director on July 1, 2026. While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure is the appointment of Shomali, which includes detailed biographical information and her effective date. The resignation is noted as non-contentious and without disagreement. The appointment of a new director to the board is a material governance event affecting the composition of the Company's leadership and oversight structure.
View raw filing on EDGAR →